We are international
Donate
TEXT SIZE   

Velcade Videos

Research
12.17.07   Dr. Beksac - Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide(T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma
Meral Beksac, MD
Ankara University
Ibn Sina Hospital
Ankara, Turkey
Member, IMF Board of Scientific Advisors

06.10.07   Bart Barlogie, MD, PhD
Arkansas Cancer Research Center
Little Rock, Arkansas, USA
Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma.

03.11.08   Velcade Webcasts Archive
Webcasts from Past Medical Meetings